New hope for schizophrenia? drug MP-214 tested in 38 patients
NCT ID NCT01626859
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at a new drug called MP-214 in 38 adults with schizophrenia. The goal was to see how safe the drug is, how the body processes it, and whether it helps control symptoms. Participants took the drug for 12 weeks, and researchers monitored side effects and drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study site
Sakai, Osaka, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?